Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD
The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.
Why Sexual and Gender Minority Care is an Oncologic Imperative
Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.
Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma
Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.
Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML
Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.
